Erratum: Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09) (Journal of Clinical Oncology (2020) DOI: 10.1200/JCO.19.00931)

Jang Ho Cho; Sung Hee Lim; Ho Jung An; Ki Hwan Kim; Keon Uk Park; Eun Joo Kang; Yoon Hee Choi; Mi Sun Ahn; Myung Hee Lee; Jong Mu Sun; Se Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung Ju Ahn

doi:10.1200/JCO.20.00446

Erratum: Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09) (Journal of Clinical Oncology (2020) DOI: 10.1200/JCO.19.00931)

Jang Ho Cho, Sung Hee Lim, Ho Jung An, Ki Hwan Kim, Keon Uk Park, Eun Joo Kang, Yoon Hee Choi, Mi Sun Ahn, Myung Hee Lee, Jong Mu Sun, Se Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung Ju Ahn

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The February 10, 2020, article by Cho et al, entitled “Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)” (J Clin Oncol 10.1200/JCO.19.00931), was published with an error.

Original language	English
Pages (from-to)	1248
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	38
Issue number	11
DOIs	https://doi.org/10.1200/JCO.20.00446
Publication status	Published - 2020 Apr 10

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.20.00446

Fingerprint

Dive into the research topics of 'Erratum: Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09) (Journal of Clinical Oncology (2020) DOI: 10.1200/JCO.19.00931)'. Together they form a unique fingerprint.

Cite this

Cho, J. H., Lim, S. H., An, H. J., Kim, K. H., Park, K. U., Kang, E. J., Choi, Y. H., Ahn, M. S., Lee, M. H., Sun, J. M., Lee, S. H., Ahn, J. S., Park, K., & Ahn, M. J. (2020). Erratum: Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09) (Journal of Clinical Oncology (2020) DOI: 10.1200/JCO.19.00931). Journal of Clinical Oncology, 38(11), 1248. https://doi.org/10.1200/JCO.20.00446

Erratum : Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09) (Journal of Clinical Oncology (2020) DOI: 10.1200/JCO.19.00931). / Cho, Jang Ho; Lim, Sung Hee; An, Ho Jung et al.

In: Journal of Clinical Oncology, Vol. 38, No. 11, 10.04.2020, p. 1248.

Research output: Contribution to journal › Comment/debate › peer-review

Cho, JH, Lim, SH, An, HJ, Kim, KH, Park, KU, Kang, EJ, Choi, YH, Ahn, MS, Lee, MH, Sun, JM, Lee, SH, Ahn, JS, Park, K & Ahn, MJ 2020, 'Erratum: Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09) (Journal of Clinical Oncology (2020) DOI: 10.1200/JCO.19.00931)', Journal of Clinical Oncology, vol. 38, no. 11, pp. 1248. https://doi.org/10.1200/JCO.20.00446

@article{93192c1f46064154a12026ca488e8352,

title = "Erratum: Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09) (Journal of Clinical Oncology (2020) DOI: 10.1200/JCO.19.00931)",

abstract = "The February 10, 2020, article by Cho et al, entitled “Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)” (J Clin Oncol 10.1200/JCO.19.00931), was published with an error.",

author = "Cho, {Jang Ho} and Lim, {Sung Hee} and An, {Ho Jung} and Kim, {Ki Hwan} and Park, {Keon Uk} and Kang, {Eun Joo} and Choi, {Yoon Hee} and Ahn, {Mi Sun} and Lee, {Myung Hee} and Sun, {Jong Mu} and Lee, {Se Hoon} and Ahn, {Jin Seok} and Keunchil Park and Ahn, {Myung Ju}",

year = "2020",

month = apr,

day = "10",

doi = "10.1200/JCO.20.00446",

language = "English",

volume = "38",

pages = "1248",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "11",

}

TY - JOUR

T1 - Erratum

T2 - Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09) (Journal of Clinical Oncology (2020) DOI: 10.1200/JCO.19.00931)

AU - Cho, Jang Ho

AU - Lim, Sung Hee

AU - An, Ho Jung

AU - Kim, Ki Hwan

AU - Park, Keon Uk

AU - Kang, Eun Joo

AU - Choi, Yoon Hee

AU - Ahn, Mi Sun

AU - Lee, Myung Hee

AU - Sun, Jong Mu

AU - Lee, Se Hoon

AU - Ahn, Jin Seok

AU - Park, Keunchil

AU - Ahn, Myung Ju

PY - 2020/4/10

Y1 - 2020/4/10

N2 - The February 10, 2020, article by Cho et al, entitled “Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)” (J Clin Oncol 10.1200/JCO.19.00931), was published with an error.

AB - The February 10, 2020, article by Cho et al, entitled “Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)” (J Clin Oncol 10.1200/JCO.19.00931), was published with an error.

UR - http://www.scopus.com/inward/record.url?scp=85084486948&partnerID=8YFLogxK

U2 - 10.1200/JCO.20.00446

DO - 10.1200/JCO.20.00446

M3 - Comment/debate

AN - SCOPUS:85084486948

SN - 0732-183X

VL - 38

SP - 1248

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 11

ER -

Erratum: Osimertinib for patients with non–small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09) (Journal of Clinical Oncology (2020) DOI: 10.1200/JCO.19.00931)

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this